Position on supplementary protection certificates for medicinal products
Posted in category:
Statement
Published on:
In this joint statement, several civil society organisations have expressed their major concerns about the role of supplementary protection certificates (SPCs) in the accessibility and price of medicines in the Netherlands and elsewhere in Europe.
have been introduced to stimulate the innovation of new medicines in the European Union, as well as to compensate companies for the time needed to acquire market authorisation for a medicine. However, research has shown no evidence that SPCs contribute to the innovation of new drugs.
The organisations therefore call for a thorough reform of intellectual property rights for medicines, starting with SPCs. The statement (see below) is in Dutch.
Partners
-
Aidsfonds
-
Commons Network
-
Health Action International (HAI)
-
Farma ter Verantwoording
Download
Related news
-
EU health data law rolls out the red carpet for Big TechPosted in category:Long read
Irene SchipperPublished on: -
Civil society coalition urges EU to put the interests of patients and citizens at the heart of the European Health Data SpacePosted in category:Published on:Statement
-
